Patients enrolled in AIDS Drug Assistance Programs (ADAPs) with chronic hepatitis C will now have free access to a new combination drug therapy.  Schering-Plough Corporation announced in late February that it will provide a new combination therapy of  PEG-INTRON (peginterferon alfa-2b) Powder for Injection and REBETOL (ribavirin USP) Capsules free to 1,500 ADAP patients through their new program Commitment To Community.  ADAPs provide critical prescription drug coverage for low-income people with HIV and AIDS who have little or no drug coverage and who otherwise would be unable to pay for these high-cost therapies.  For details on this new initiative, click HERE to view the National Alliance of State and Territorial AIDS Directors’ (NASTAD) press release.